drugset / Trial / NCT03808935
Cannabis Extract in Refractory Epilepsy Study
Phase 3
Terminated
17 enrolled
The Epilepsy Research Program of the Ontario Brain Institute
London Health Sciences Centre · collabMedReleaf · collabOntario Brain Institute · collabUniversity Health Network, Toronto · collabUniversity of Toronto · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to examine whether a low dose of CBD+THC will decrease the frequency of convulsive seizures in adults with drug-resistant epilepsy, when used in addition to standard anti-epileptic drugs (AEDs). This study will also study the genes associated with epilepsy and whether different epileptic syndromes respond to treatment with CBD+THC.
Timeline
- Start
- 2019-01-10
- Primary completion
- 2020-03-15
- Completion
- 2020-03-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cannabidiol | Other / unclassified | 300 mg | — |